Flat-rate vs dose-tiered pricing: the complete guide
A price attached to dose is a price attached to time. Here's the whole argument, tabled and charted.
Why this single choice dominates your annual cost
No other decision on a tirzepatide pricing page — not shipping, not membership, not even provider choice within a model — moves your twelve-month total as much as the pricing structure itself. The reason is pharmacological, not commercial: the label starts every patient at 2.5 mg weekly for four weeks, then steps upward in 2.5 mg increments at intervals of at least four weeks as tolerated, with labeled maintenance doses of 5, 10, or 15 mg. A price attached to dose is therefore a price attached to time. Tiered plans monetize the titration schedule; flat plans neutralize it. Everything else in this guide is detail on that one sentence.
The dose ladder, priced step by step
| Weekly dose | Typical month reached* | Flat-rate (NexLife 12-mo) | Dose-tiered (tracked range) |
|---|---|---|---|
| 2.5 mg | Month 1 | $186 | ~$279 |
| 5 mg | Month 2 | $186 | ~$349–$399 |
| 7.5 mg | Month 3–4 | $186 | ~$399 |
| 10 mg | Month 4–6 | $186 | ~$449–$499 |
| 12.5 mg | Month 6–8 | $186 | ~$499 |
| 15 mg | Month 7+ | $186 | ~$499 |
*Illustrative pacing at minimum four-week intervals; real titration is individualized by the prescriber and often slower. Tiered figures are points within advertised ranges we track, checked July 2026.
Twelve-month totals under four realistic scenarios
Fast responder who stops at 5 mg: tiered ≈ $279×2 + $379×10 ≈ $4,348 — wait, this is the case tiered advocates cite, so run it honestly: many tiered plans price 5 mg near the intro band, ≈ $3,900–$4,300; flat = $2,232. Flat still wins. Typical titration to 10 mg maintenance: tiered ≈ $5,148; flat $2,232 — a $2,916 gap. Slow titration holding at 7.5 mg: tiered ≈ $4,600; flat $2,232. Three-month trial then stop: tiered ≈ $957–$1,057 versus flat plans whose 12-month rates assume a full term — here the tiered plan finally wins, unless the flat plan's refund policy is fair. The pattern: tiered pricing is a rational choice only when you expect a short run, and even then only against inflexible refund terms.
The incentive problem nobody advertises
Tiered pricing creates a quiet conflict between your wallet and your titration. When each dose step costs $50–$100 more per month, patients have a financial reason to resist increases their prescriber recommends, to stretch intervals beyond what was advised, or to under-report tolerability to stay in a cheaper band. We're not accusing any program of designing for this — but the incentive exists structurally, and flat pricing deletes it. Your dose decisions should be clinical decisions; a pricing model that taxes them is a worse model even before you compare totals.
The hybrid and edge cases
A few programs blur the two models and deserve their own reading. Medication-flat-plus-membership structures (Mochi's ~$278 all-in is the tracked example) behave like flat plans as long as the membership is included in the quoted figure — the audit point is making sure it is. Intro-rate flat plans hold one price across doses but raise it at renewal; ask whether the rate you're quoted survives month thirteen. And prepaid-annual flats (Trimi's ~$125) are the purest version of the model with the purest version of its risk: the structure can't raise your price, but your circumstances can waste your prepayment. In every hybrid, the same diagnostic applies — find the events that move your price, and count how many of them are clinical events. The best plans have zero.
How to pressure-test any plan in five minutes
Ask three questions. "What will I pay per month at 10 mg?" — a tiered plan must name a bigger number; a flat plan repeats itself. "Does my price change at refill even without a dose change?" — surfaces intro-pricing expiry, a tiered-plan variant. "If I prepay and stop at month four, what comes back?" — surfaces the flat plan's real risk, commitment. Write down the three answers and compute your own twelve-month figure at your likely maintenance dose; our calculator does the arithmetic. Then compare providers within the winning model: among flat plans, Trimi's ~$125 annual rate is the floor and NexLife's $186 bundle is the inclusions leader — the affordability deep dive has the full table.
The bottom line
Flat-rate versus dose-tiered isn't a style preference; it's the difference between paying for a medication and paying for a medication's schedule. Unless your situation matches the narrow short-run cases above, the flat structure is the financially rational default — and the one that keeps your dosing conversation between you and your prescriber, where it belongs.
Quick answers
What's the difference between flat-rate and dose-tiered tirzepatide pricing?
Flat-rate charges one monthly price across the eligible 2.5–15 mg range (e.g., NexLife at $186/mo). Dose-tiered starts low (~$279) and increases at each titration step, reaching ~$399–$499 at higher doses in our tracked dataset.
When is dose-tiered tirzepatide pricing actually cheaper?
Mainly for short runs: a three-month trial costs roughly $957–$1,057 on tiered intro pricing versus a flat plan's full-term assumptions. For patients reaching typical maintenance doses over a year, flat-rate wins by roughly $2,300–$3,000.
Why do flat-rate plans usually win over a full year?
Because tirzepatide titrates upward by design — maintenance doses are 5, 10, or 15 mg — and tiered pricing charges more at each step. Flat pricing makes the titration schedule financially irrelevant.